

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT LICENSE AGREEMENT WITH ALPHAMAB AND GLENMARK FOR ENVAFOLIMAB

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to update shareholders of the Company and potential investors with the latest business development of the Group.

LICENSE AGREEMENT WITH ALPHAMAB AND GLENMARK

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, 3D Medicines and Jiangsu Alphamab (the “**Licensors**”), and Glenmark (the “**Licensee**”) entered into a license agreement (the “**License Agreement**”) on January 24, 2024, pursuant to which, the Licensors agreed to grant the Licensee an exclusive license and the right to sublicense in respect of oncology indications of Envafolimab, also known as “KN035” (brand name: ENWEIDA, 恩維達®) (a recombinant humanized single domain antibody against PD-L1 co-developed by the Group and the Alphamab Group) to, among others, (a) develop Envafolimab in India, Asia Pacific (except Singapore, Thailand and Malaysia), Middle-east and Africa, Russia, the Commonwealth of Independent States and Latin America (the “**Territory**”) for the purpose of commercialization in all field of use in oncology (the “**Field**”) in the Territory; and (b) commercialize Envafolimab in the Field in the Territory, subject to the terms and conditions of the License Agreement. The Licensee will develop and commercialize Envafolimab in the Field in the Territory at its own cost and expense.

Under the License Agreement, the Licensors will receive from the Licensee (a) a total of up to US\$700.8 million of a non-refundable upfront payment and milestones payments subject to the achievement of certain development, regulatory and commercialization milestones; and (b) a single to double digits percentages royalty fees according to the level of net sales of Envafolimab. The Licensors’ respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between the 3D Medicines and Jiangsu Alphamab. Jiangsu Alphamab retains its sole right to manufacture Envafolimab for any purpose within or outside the Territory.

3D Medicines retains the right to develop and commercialize Envafolimab for any purpose in the Field outside the Territory.

The Company believes that such cooperation will enable the Company to effectively utilize the existing team and resources of Glenmark, rapidly establish a favorable market position for Envafohimab in the Territory and the implementation of the License Agreement will have a positive impact on the commercialization of Envafohimab in the Territory. The terms of the License Agreement were determined after arm's length negotiation between relevant parties. The Company also believes that the License Agreement is in the interests of the Company and its shareholders as a whole.

INFORMATION ON THE PARTIES INVOLVED

Jiangsu Alphamab and Alphamab

Jiangsu Alphamab was established in China on July 14, 2015, primarily engaging in research and development, manufacturing and commercialization of biologics of oncology. It is a wholly-owned subsidiary and the principal operating subsidiary of Alphamab.

Alphamab is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of Alphamab includes the oncology drug candidates with one approved for marketing by the NMPA, three in late clinical stage and two in phase I clinical trial stage. Alphamab has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, Alphamab is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Glenmark and Glenmark Pharmaceuticals Ltd.

Glenmark is wholly owned by Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, the shares of which are listed on the Bombay Stock Exchange (stock code: 532296) and the National Stock Exchange of India Limited (ticker symbol: GLENMARK), having a presence across brand name drug, generic drug, and over-the-counter drug segments with a focus on therapeutic areas of respiratory, dermatology and oncology.

To the best knowledge and belief of the Company, each of Glenmark and Jiangsu Alphamab is independent of, and not connected with, the Company and/or its connected persons. The transactions contemplated under the License Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

ABOUT ENVAFOLIMAB (brand name: ENWEIDA, 恩維達®)

Envafohimab is a recombinant single domain antibody against PD-L1 fused with human Fc, a drug co-developed with the Alphamab Group since 2016. It has been approved by the National Medical Products Administration of China (國家藥品監督管理局) ("NMPA") as the global-first subcutaneous injection PD-L1 inhibitor in November 2021.

ABOUT THE COMPANY

3D Medicines Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines Inc. focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines Inc. has established a pipeline with both biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“3D Medicines”	3D Medicines (Beijing) Co., Ltd. (思路迪(北京)醫藥科技有限公司), a company incorporated under the laws of the PRC on December 22, 2014, and an indirect non-wholly owned subsidiary of the Company, collaborating with the Alphamab Group in the development of Envafolelimab
“Alphamab”	Alphamab Oncology (康寧傑瑞生物製藥), an exempted company with limited liability incorporated under the laws of the Cayman Islands on March 28, 2018 and listed on the Stock Exchange (stock code: 9966)
“Alphamab Group”	Alphamab and its subsidiaries
“Company”	3D Medicines Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands and the shares of which are listed on the main board of the Stock Exchange (stock code: 1244)
“Glenmark”	Glenmark Specialty S.A., a corporation organized and existing under the laws of Neuchâtel, Switzerland, wholly owned by Glenmark Pharmaceuticals Ltd.
“Jiangsu Alphamab”	Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (also known as Jiangsu Alphamab Pharmaceuticals Co., Ltd.) (江蘇康寧傑瑞生物製藥有限公司), a limited liability company established in PRC on July 14, 2015 and a wholly owned subsidiary of Alphamab
“PD-L1”	programmed death ligand 1, a protein on the surface of a normal cell or a cancer cell that can attach to programmed cell death protein 1 on the surface of the T-cell that causes the T-cell to turn off its ability to kill the cancer cell
“PRC”	the People’s Republic of China excluding, for the purposes of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan region
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

Cautionary Statement required by Rule 18A.05 and Rule 18A.08(3) of the Listing Rules: The Company may not be able to successfully develop and/or market its core product Envafolelimab 恩維達® (also known as KN035) for indications other than the approved indication in previously treated MSI-H/dMMR advanced solid tumors. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, January 25, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.